Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY900027 · 1 trial · 1 indication
PK: AUC after Bolus Administration Prior to a MMTT
PK: C PK: Cmax
| Arm | Type | Description |
|---|---|---|
| LY900027 | EXPERIMENTAL | LY900027 administered to participants with type 1 diabetes mellitus (T1DM) using continuous subcutaneous insulin infusion (CSII) in one of two dosing periods. |
| Insulin Lispro | ACTIVE_COMPARATOR | Insulin lispro administered to participants with T1DM using CSII in one of two dosing periods. |
| Name | Type | Description |
|---|---|---|
| LY900027 | DRUG | LY900027 administered to participants with T1DM using CSII. |
| Insulin Lispro | DRUG | Insulin lispro administered to participants with T1DM using CSII. |
Inclusion Criteria: * Diagnosis of T1DM for at least 1 year * Fasting C-peptide ≤0.30 nanomoles per liter (nmol/L) * Bbody mass index between 18.5 and 33.0 kilograms per square meter (kg/m²) * Participants should have a glycated hemoglobin of ≤9.0% at screening Exclusion Criteria:
LY900027 is an investigational small molecule being studied for the treatment of Type 1 Diabetes Mellitus. It is administered via an insulin pump. The drug is in Phase 1 clinical development and is not yet approved for any use.
LY900027 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 1 Diabetes Mellitus.
LY900027 is in Phase 1 clinical development. A Phase 1 trial has been completed, but the drug remains investigational and has not been approved by regulatory authorities. Further clinical studies would be needed to assess its potential for approval.
LY900027 has one completed Phase 1 clinical trial, identified as NCT04161976. This study, titled 'A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus,' enrolled 20 participants in Germany. The trial was randomized, double-blind, and active-controlled.
LY900027 is a small molecule, but its specific molecular target has not been disclosed. The drug is being studied for use in Type 1 Diabetes Mellitus and is administered through an insulin pump, suggesting it may be designed to work in conjunction with insulin delivery systems.